acut
respiratori
failur
occur
half
patient
haematolog
malign
solid
tumour
solid
organ
transplant
mortal
remain
high
factor
associ
mortal
includ
need
invas
mechan
ventil
organ
dysfunct
older
age
frailti
poor
perform
statu
delay
intens
care
unit
admiss
acut
respiratori
failur
due
invas
fungal
infect
unknown
caus
addit
appropri
antibacteri
therapi
initi
clinic
manag
aim
restor
oxygen
predict
probabl
caus
base
variabl
relat
underli
diseas
acut
respiratori
failur
characterist
radiograph
find
caus
acut
respiratori
failur
must
confirm
use
effici
least
invas
safest
diagnost
test
patient
acut
respiratori
failur
undet
mine
caus
standardis
diagnost
investi
gation
done
immedi
admiss
decid
whether
perform
invas
diagnost
procedur
start
empir
treatment
collabor
multidisciplinari
clinic
research
network
crucial
improv
understand
diseas
pathogenesi
causat
develop
less
invas
diagnost
strategi
target
treatment
option
wwwthelancetcomrespiratori
vol
grow
number
adult
immun
dysfunct
gener
popul
cancer
survivor
transplant
rise
immunosuppress
drug
use
indic
moreov
intens
treatment
improv
diseasefre
surviv
also
increas
risk
lifethreaten
event
mani
affect
lung
acut
respiratori
failur
defin
triad
clinic
sign
radiograph
find
ga
exchang
alter
patient
present
newli
develop
worsen
respiratori
symptom
period
day
sever
acut
respiratori
failur
manifest
respiratori
distress
sever
tachypnoea
labour
breath
recruit
accessori
respiratori
muscl
variou
pattern
pulmonari
infiltr
might
seen
common
diffus
bilater
infiltr
patient
acut
respiratori
failur
requir
oxygen
therapi
studi
acut
respiratori
failur
includ
patient
receiv
lmin
standard
oxygen
howev
depend
countri
number
avail
hospit
bed
patient
acut
respiratori
failur
manag
ward
intermedi
care
unit
intens
care
unit
icu
overal
need
icu
admiss
need
invas
mechan
ventil
imv
mortal
increas
requir
oxygen
flow
thu
patient
requir
lmin
standard
oxygen
need
intub
throughout
icu
stay
mortal
hospit
discharg
delay
icu
admiss
associ
increas
mortal
immunocompromis
patient
acut
respiratori
failur
encount
clinician
daili
practic
review
look
epidemiolog
outcom
diagnost
investig
immunocompromis
patient
acut
respiratori
failur
emphasi
broad
rang
caus
must
consid
discuss
role
invas
noninvas
test
identif
caus
acut
respiratori
failur
although
huge
divers
test
avail
caus
coupl
scarciti
randomis
control
trial
creat
major
challeng
also
suggest
approach
manag
hypoxaemia
base
latest
literatur
incid
respiratori
event
vari
across
differ
group
immunocompromis
patient
tabl
studi
follow
cohort
patient
main
object
collect
inform
incid
pulmonari
infiltr
respiratori
complic
observ
studi
shown
among
haematolog
malign
lymphoprolif
di
order
acut
lymphoblast
leukaemia
lymph
oma
associ
moder
incid
respiratori
event
compar
acut
myeloid
leukaemia
myelodysplast
syn
drome
tabl
review
key
messag
acut
respiratori
failur
occur
haematolog
patient
primarili
patient
acut
myeloid
leukaemia
allogen
haemopoiet
stem
cell
transplant
patient
solid
tumour
chiefli
lung
cancer
solid
organ
transplant
chiefli
heart
lung
mortal
high
associ
invas
mechan
ventil
organ
dysfunct
older
age
frailti
poor
perform
statu
delay
intens
care
unit
admiss
acut
respiratori
failur
due
invas
fungal
infect
unknown
caus
addit
appropri
antibacteri
therapi
initi
manag
aim
restor
oxygen
predict
probabl
caus
basi
variabl
relat
underli
diseas
characterist
acut
respiratori
failur
radiograph
find
caus
acut
respiratori
failur
must
confirm
use
effici
least
invas
safest
diagnost
test
patient
acut
respiratori
failur
undetermin
caus
standardis
diagnost
investig
done
immedi
admiss
decid
whether
perform
invas
diagnost
procedur
start
empir
treatment
collabor
multidisciplinari
clinic
research
network
crucial
improv
understand
diseas
pathogenesi
causat
develop
less
invas
diagnost
strategi
target
treatment
option
patient
prolong
neutropenia
autolog
allogen
stem
cell
transplant
recipi
higher
incid
respiratori
event
compar
haematolog
patient
solid
tumour
associ
lower
incid
respiratori
event
haematolog
malign
lung
cancer
highest
rate
endobronchi
obstruct
atelectasi
risk
factor
pneu
monia
howev
patient
breast
cancer
treat
radiat
paclitaxel
crude
rate
pneumon
ci
note
patient
cancer
receiv
immunotherapi
mostli
program
med
death
program
death
ligand
inhibitor
incid
pneumon
reach
acut
respiratori
failur
occur
kidney
transplant
recipi
heart
lung
transplant
recipi
overal
mortal
among
patient
acut
respiratori
failur
depend
underli
condit
natur
sever
cours
respiratori
failur
need
imv
associ
organ
dysfunct
sever
studi
assess
risk
factor
mortal
immunocompromis
patient
acut
respiratori
failur
factor
group
five
categori
factor
reflect
sever
acut
respiratori
failur
associ
organ
dysfunct
factor
relat
delay
icu
admiss
factor
relat
underli
diseas
comorbid
condit
factor
relat
initi
oxygen
ventil
strategi
factor
relat
caus
acut
respiratori
failur
hypoxaemia
hallmark
respiratori
failur
clinic
sign
toler
hypoxaemia
usual
function
respiratori
symptom
durat
instanc
acut
hypoxaem
episod
lead
respiratori
distress
within
hour
wherea
subacut
nonacut
lung
insult
similar
magnitud
result
deep
hypoxaemia
without
sign
respiratori
distress
overal
degre
hypoxaemia
reflect
extent
lung
involv
hypoxaemia
measur
directli
pao
room
air
assess
basi
oxygen
flow
need
achiev
peripher
capillari
oxygen
satur
spo
estim
calcul
ratio
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
pao
fio
ratio
use
mani
year
riskstratifi
patient
guid
icu
admiss
decis
increas
oxygen
flow
associ
need
icu
admiss
need
imv
hospit
mortal
similarli
lower
pao
fio
associ
mortal
patient
acut
respiratori
distress
syndrom
need
noninvas
ventil
niv
failur
highflow
nasal
oxygen
therapi
hfno
persist
tachypnoea
also
associ
failur
standard
oxygen
niv
highflow
nasal
cannula
requir
impl
mentat
anoth
strategi
eg
intub
studi
evalu
impact
hyperoxygen
set
associ
organ
dysfunct
best
depict
sequenti
organ
failur
assess
sofa
score
consist
identifi
determin
mortal
higher
score
associ
increas
mortal
delay
icu
admiss
associ
increas
mortal
immuno
comprom
ise
patient
particularli
acut
respiratori
failur
benefit
earlier
icu
admiss
might
result
care
clinic
assess
optim
oxygen
strategi
avoid
potenti
harm
investig
select
least
invas
diag
nostic
test
icu
characterist
underli
immuno
suppress
condit
usual
associ
hospit
mortal
follow
icu
admiss
although
variat
occur
depend
icu
admiss
polici
higher
proport
patient
admit
icu
donotresuscit
donotintub
statu
result
stronger
associ
variabl
reflect
characterist
diseas
statu
mortal
perform
statu
comorbid
associ
increas
mortal
effect
initi
oxygen
ation
ventil
strategi
mortal
discuss
later
review
furthermor
previous
mention
sever
studi
assess
associ
caus
acut
respiratori
failur
mortal
mortal
lowest
patient
cardiac
pulmonari
oedema
highest
invas
fungal
infect
identifi
caus
acut
respiratori
failur
earli
assess
pretest
probabl
acut
respiratori
failur
caus
one
first
key
step
earli
manag
immunocompromis
patient
acut
respiratori
fail
ure
establish
probabl
caus
acut
respiratori
failur
bedsid
base
clinic
examin
undertak
test
standard
combin
therapi
suitabl
patient
acut
respiratori
failur
patient
must
consid
individu
clinician
make
everi
effort
identifi
caus
acut
respiratori
failur
patient
high
risk
intub
mortal
eg
higher
sofa
score
hypoxaem
bacteri
infect
main
caus
acut
respiratori
failur
patient
receiv
antibacteri
drug
soon
admiss
cardiogen
pulmonari
oedema
must
consid
everi
patient
howev
diagnos
consid
casebycas
basi
thu
basic
diagnost
investig
patient
panel
includ
test
cardiogen
pulmonari
oedema
sputum
examin
blood
cultur
detect
bacteri
fungal
infect
induc
sputum
exam
inat
pneumocysti
viral
multiplex
pcr
nasopharyng
aspir
swab
viral
pcr
plasma
blood
assess
likelihood
underli
condit
treatment
affect
lung
analysi
imag
data
perform
first
clinic
examin
mnemon
direct
use
assess
caus
acut
respiratori
failur
bedsid
refer
respiratori
symptom
durat
day
type
immunosuppress
r
chest
xray
pattern
e
clinician
experi
similar
case
c
clinic
find
highresolut
ct
patient
myeloprolif
diseas
acut
myeloid
leukaemia
myelodysplast
syndrom
chronic
myeloid
leukaemia
case
acut
respir
atori
failur
occur
earli
diseas
onset
relat
leukaem
infiltr
figur
although
patient
might
present
pneumonia
cardiogen
pulmonari
oedema
acut
respiratori
failur
infecti
origin
howev
common
earliest
phase
lympho
prolif
disord
figur
acut
lymphoblast
leukaemia
lymphoma
patient
tcell
prolifer
opportunist
infect
report
cancer
treatment
initi
ex
emplifi
role
play
diseaserel
immuno
suppress
later
followup
infect
main
caus
figur
although
treatmentrel
toxic
diseas
relaps
also
lead
acut
respiratori
failur
clinician
struggl
noninfecti
caus
whose
diagnosi
believ
reli
sole
biopsi
difficult
obtain
hypoxaem
patient
thrombocytopenia
haemostat
disord
bronchoscopi
bronchoalveolar
lavag
report
possibl
deterior
respiratori
statu
increas
imv
need
howev
multidisciplinari
collabor
approach
allow
earlier
recognit
typic
pattern
clinic
laboratori
find
addit
al
diagnost
procedur
need
lung
infiltr
underli
condit
leukaem
infiltr
patient
acut
myeloid
leukaemia
diffus
alveolar
haemorrhag
cytarabinerel
pul
monari
toxic
immuno
therapyrel
pneu
moniti
etc
patient
pattern
often
consid
known
caus
acut
respiratori
failur
multidisciplinari
team
make
appropri
diagnosi
similarli
condit
neutro
penia
allogen
haemopoiet
stem
cell
tran
plantat
associ
high
risk
respiratori
event
specif
acut
respiratori
failur
caus
exacerb
previou
lung
injuri
neutropenia
recoveri
noninfecti
interstiti
lung
diseas
follow
haemo
poietic
stem
cell
transplant
acut
respiratori
failur
first
day
solid
organ
transplant
probabl
relat
either
biopsi
punctur
extrapulmonari
involv
skin
joint
peripher
lymph
node
sternal
punctur
buccal
smear
etc
imag
data
includ
chest
xray
lung
pleural
echographi
highresolut
ct
scan
without
firstlin
contrast
media
unless
clinic
suspicion
pulmonari
vascular
diseas
review
surgic
complic
decompens
chronic
respiratori
cardiac
comorbid
condit
invas
candidiasi
might
occur
quit
earli
transplant
howev
opportunist
infect
report
month
transplant
depend
heavili
adher
prophylact
regimen
patient
note
use
intens
immuno
suppress
patient
experienc
acut
humor
interstiti
reject
use
immuno
suppress
drug
combin
ensur
graft
toler
clinician
must
care
assess
individu
risk
possibl
caus
perform
complet
diagnost
investig
individu
case
type
immun
defici
must
assess
allow
appropri
adjust
initi
antiinfecti
treatment
figur
avoid
treatment
delay
imag
studi
particularli
highresolut
ct
anoth
import
bedsid
tool
determin
caus
acut
respiratori
failur
review
detail
radiolog
find
immunocompromis
patient
acut
respiratori
failur
pattern
lung
involv
import
piec
puzzl
predict
specif
caus
howev
combin
posit
neg
highresolut
ct
find
suggest
specif
caus
lung
infiltr
differ
compon
direct
mnemon
contribut
determin
pretest
clinic
probabl
individu
diagnosi
figur
given
clinic
situat
relat
differ
caus
acut
respiratori
failur
contextu
element
clinic
find
vari
across
patient
howev
administr
antifung
drug
antipneumocysti
therapi
delay
pretest
probabl
diseas
substanti
noninvas
diagnost
test
offer
altern
bronchoscopi
bronchoalveolar
lavag
carri
risk
respiratori
deterior
requir
imv
howev
bronchoalveolar
lavag
might
requir
noninvas
respiratori
sampl
either
feasibl
poor
qualiti
perform
bronchoalveolar
lavag
support
niv
highflow
nasal
cannula
help
patient
toler
procedur
also
firstlin
bronchoalveolar
lavag
must
consid
situat
patient
possibl
diagnosi
diffus
alveolar
haemorrhag
pneumocysti
jirovecii
pneumonia
drugrel
pul
monari
toxic
lung
infiltr
might
involv
underli
diseas
vascul
lymphoma
etc
diagnost
yield
noninvas
test
howev
increas
sinc
introduct
sensit
diagnost
test
pcr
howev
test
sensit
specif
clinic
relev
posit
pcr
sometim
uncertain
patient
cancer
standard
diagnost
investig
done
immedi
icu
admiss
includ
physic
examin
pretest
probabl
assess
use
direct
sputum
possibl
induc
sputum
examin
nasopharyng
aspir
swab
blood
cultur
serum
urin
antigen
assay
imag
studi
biomark
assay
noninvas
test
perform
well
bronchoscopi
bronchoalveolar
lavag
solid
organ
transplant
recipi
howev
bronchoalveolar
lavag
higher
diagnost
yield
although
riskbenefit
ratio
assess
popul
moreov
advent
omic
assist
diagnosi
infect
well
sophist
immunolog
molecular
biolog
method
advanc
imag
techniqu
establish
diagnosi
noninfecti
condit
reapprais
diagnost
yield
noninvas
test
immunocompromis
patient
warrant
nevertheless
despit
optim
earli
diagnost
investig
caus
remain
undetermin
tabl
failur
identifi
caus
acut
respiratori
failur
independ
associ
mortal
sever
studi
patient
caus
acut
respiratori
failur
identifi
late
impact
late
diagnos
correspondingli
late
treatment
assess
associ
absenc
document
caus
mortal
rais
sever
question
tabl
associ
might
relat
part
patient
die
within
hour
intract
hypoxaemia
multipl
organ
dysfunct
diagnost
test
perform
provid
expert
opinion
care
attent
direct
clinic
situat
underli
diseas
comorbid
condit
ongo
longterm
treatment
well
respons
treatment
given
current
acut
respiratori
failur
episod
figur
show
firstlin
diagnost
strategi
accord
clinic
radiograph
present
expert
also
sometim
difficult
task
determin
test
actual
perform
obtain
exact
result
oppos
classif
posit
neg
potenti
obtain
result
might
yet
made
avail
bedsid
physician
awar
lung
biopsi
often
feasibl
due
haemodynam
instabl
deep
hypoxaemia
review
acut
respiratori
failur
receiv
imv
time
biopsi
nonintub
patient
cohort
haematolog
patient
diagnost
yield
lung
biopsi
therapeut
yield
diagnost
yield
lower
patient
imv
neutropenia
higher
patient
focal
infiltr
invas
aspergillosi
also
common
biopsi
find
studi
complic
occur
patient
preval
invas
aspergillosi
line
data
acut
respiratori
distress
syndrom
patient
cancer
autopsi
find
patient
acut
respiratori
distress
syndrom
haematolog
patient
includ
lung
biopsi
obtain
postmortem
inflammatori
malign
infiltr
common
diagnos
retro
spectiv
autopsi
studi
haemopoiet
stem
cell
transplant
recipi
show
fungal
infect
potenti
steroidrespons
lung
involv
ment
malign
infiltr
underdiagnos
compli
cation
associ
ate
lung
biopsi
occur
patient
highli
select
base
platelet
count
perform
statu
goal
care
given
lower
diagnost
yield
lung
biopsi
icu
patient
riskbenefit
ratio
favour
therefor
lung
biopsi
rare
perform
critic
ill
immuno
compromis
patient
acut
respiratori
failur
lung
infiltr
unknown
caus
howev
minim
invas
ctguid
lung
biopsi
transbronchi
cryobiopsi
increasingli
done
studi
assess
time
minim
invas
diagnost
techniqu
set
warrant
diagnost
yield
better
defin
identif
new
diagnosi
detect
less
invas
techniqu
result
chang
treatment
moreov
riskbenefit
ratio
need
reassess
minim
invas
biopsi
techniqu
evalu
randomis
control
trial
control
patient
receiv
empir
treatment
common
lung
biopsi
diagnos
name
invas
fungal
infect
steroidrespons
lung
diseas
panel
initi
oxygen
ventil
strategi
aim
restor
safe
oxygen
reduc
respiratori
rate
allevi
dyspnoea
respiratori
distress
improv
patient
comfort
past
two
decad
studi
consist
shown
higher
mortal
immunocompromis
patient
requir
imv
prioriti
therefor
given
avoid
imv
use
noninvas
oxygen
ventil
devic
figur
howev
failur
niv
hfno
associ
higher
mortal
two
older
studi
even
suggest
earli
imv
associ
improv
surviv
furthermor
respiratori
diseas
sever
associ
organ
dysfunct
usual
wors
intub
patient
determin
whether
excess
mortal
patient
imv
due
imv
greater
sever
acut
ill
difficult
word
focu
avoid
intub
might
effect
need
imv
might
identifi
group
patient
high
diseas
sever
overal
five
initi
oxygen
method
avail
patient
hypoxaem
acut
respiratori
failur
figur
guidelin
european
respiratori
societi
american
thorac
societi
advoc
use
niv
recommend
base
mainli
singlecentr
trial
patient
mortal
group
assign
standard
oxygen
highest
ever
report
set
trial
show
neither
benefit
harm
niv
sharp
contrast
posthoc
analysi
trial
frat
colleagu
compar
outcom
immunocompromis
patient
treat
hfno
niv
standard
oxygen
trial
imv
mortal
rate
higher
niv
group
compar
hfno
standard
oxygen
group
result
consist
studi
report
increas
risk
failur
mortal
patient
receiv
niv
sever
acut
respiratori
distress
syndrom
thu
data
rais
concern
use
niv
immunocompromis
patient
hypoxaem
acut
respiratori
failur
first
introduc
hfno
seem
promis
altern
niv
hfno
easi
use
deliv
humidifi
warm
oxygen
therebi
allow
high
flow
improv
toler
comfort
hfno
improv
oxygen
lower
respiratori
rate
inspiratori
effort
hfno
also
increas
endexpiratori
lung
volum
dynam
lung
complianc
physiolog
effect
even
pronounc
increas
flow
rate
deliv
howev
randomis
control
trial
unselect
patient
hypoxaem
acut
respiratori
failur
pao
fio
ratio
mm
hg
number
patient
requir
intub
significantli
reduc
hfno
compar
niv
standard
oxygen
howev
number
ventilatorfre
day
day
significantli
higher
hfno
hazard
ratio
mortal
lower
hfno
five
studi
evalu
feasibl
safeti
hfno
immunocompromis
patient
acut
respiratori
failur
retrospect
singlecentr
studi
patient
haematolog
malign
half
bone
marrow
transplant
recipi
half
recent
receiv
system
chemotherapi
neutropen
hfno
allow
recoveri
without
intub
figur
nine
oxygen
ventil
method
standard
oxygen
administ
wide
array
devic
lowflow
oxygen
system
compris
nasal
cannula
nasal
cathet
provid
supplement
oxygen
flow
total
minut
ventil
lead
oxygen
dilut
ambient
air
lower
inspir
oxygen
concentr
standard
nasal
cannula
deliv
inspiratori
fio
suppli
flow
lmin
depend
respiratori
rate
tidal
volum
humidif
devic
recommend
flow
lmin
reservoir
mask
b
deliv
fio
valu
lmin
reservoir
system
store
oxygen
flow
rate
lmin
must
set
ensur
washout
exhal
ga
avoid
co
retent
nonrebreath
facemask
c
may
deliv
fio
flow
set
lmin
use
short
period
humidif
difficult
also
risk
co
retent
mask
reservoir
bag
allow
collaps
inspir
lastli
venturi
system
mix
oxygen
room
air
humidif
necessari
provid
accur
constant
fio
despit
variat
respiratori
rate
tidal
volum
employ
concern
aris
co
retent
respiratori
drive
inconsist
highflow
oxygen
therapi
nasal
prong
cannula
highflow
nasal
oxygen
therapi
e
suppli
exact
fio
flow
equal
greater
patient
inspiratori
flow
demand
nasal
oxygen
administ
flow
rate
lmin
warm
bodi
temperatur
satur
full
humid
molecular
humidif
noninvas
positivepressur
ventil
provid
ventil
support
without
endotrach
tube
use
oronas
f
total
face
g
mask
helmet
h
main
noninvas
ventil
mode
use
hypoxaem
acut
respiratori
failur
pressur
support
continu
posit
airway
pressur
bilevel
posit
airway
pressur
use
less
often
final
invas
mechan
ventil
use
tracheal
tube
insert
trachea
gener
anaesthesia
neuromuscularblock
drug
tube
secur
face
neck
connect
ventil
patient
hypoxaem
acut
respiratori
failur
intub
invas
mechan
ventil
use
failur
standard
oxygen
case
aforement
noninvas
option
fio
fraction
inspir
oxygen
onethird
patient
hospit
mortal
rate
hfno
success
hfno
fail
hfno
failur
rate
singlecentr
studi
patient
solid
tumour
studi
haematolog
patient
phase
trial
patient
advanc
cancer
persist
dyspnoea
compar
hfno
biphas
posit
airway
pressur
oxygen
satur
improv
hfno
wherea
treatment
provid
similar
improv
dyspnoea
respiratori
rate
lung
transplant
recipi
acut
respiratori
failur
hfno
prove
feasibl
safe
decreas
absolut
risk
intub
numberneededtotreat
avoid
one
intub
although
result
trial
specif
assess
hfno
immunocompromis
patient
hypoxaem
acut
respiratori
failur
avail
six
studi
compar
hfno
oxygen
ventil
strategi
set
tabl
retrospect
cohort
patient
cancer
acut
respiratori
failur
patient
receiv
niv
plu
hfno
niv
plu
standard
oxygen
hfno
alon
standard
oxygen
alon
combin
niv
hfno
associ
lower
mortal
rate
vs
patient
independ
associ
higher
surviv
posthoc
analysi
data
invictu
randomis
control
trial
earli
niv
immunocompromis
patient
acut
respiratori
failur
neither
intub
rate
mortal
differ
significantli
hfno
arm
standard
oxygen
arm
posthoc
analysi
trial
frat
colleagu
outcom
compar
across
standard
oxygen
niv
hfno
although
niv
associ
increas
need
intub
higher
mortal
neither
paramet
differ
significantli
patient
assign
standard
oxygen
patient
assign
hfno
retrospect
studi
immuno
compromis
patient
acut
respir
atori
failur
proport
patient
requir
intub
vs
mortal
vs
higher
niv
hfno
efraim
multicentr
multin
prospect
cohort
studi
immunocompromis
patient
patient
intub
icu
admiss
receiv
standard
oxygen
hfno
niv
niv
plu
hfno
hospit
mortal
affect
initi
oxygen
ventil
manag
nonsignific
trend
toward
reduc
intub
patient
given
hfno
retrospect
studi
kidney
recipi
number
ventilatorfre
day
day
significantli
higher
hfno
group
niv
group
result
two
trial
hfno
focus
specif
immuno
compromis
adult
acut
respiratori
failur
expect
avail
month
hfno
yet
properli
evalu
regard
abil
assist
diagnost
procedur
bronchoscopi
bronchoalveolar
lavag
bronchial
transbronchi
biopsi
chang
initi
oxygen
niv
strategi
unlik
translat
improv
surviv
respons
patient
standard
oxygen
hfno
niv
care
assess
initi
strategi
standard
oxygen
niv
hfno
lower
respiratori
rate
minut
ventil
continu
continu
revalu
tachypnoea
high
respiratori
drive
persist
risk
intub
high
reason
evalu
potenti
benefit
avoid
delay
intub
ad
selfinflict
lung
injuri
initi
pulmonari
insult
earli
intub
associ
improv
surviv
haematolog
patient
studi
earli
intub
patient
persist
high
respiratori
drive
despit
initi
oxygen
strategi
warrant
summari
acut
respiratori
failur
common
often
fatal
event
immunocompromis
patient
rais
major
diagnost
therapeut
challeng
near
futur
use
intens
therapeut
regimen
design
cure
cancer
induc
transplant
toler
control
autoimmun
inflammatori
diseas
ever
older
frailer
patient
incid
acut
respiratori
failur
background
immunodefici
expect
increas
moreov
expand
use
target
therapi
immuno
therapi
lead
grow
burden
toxic
infect
increas
life
span
popul
knowledg
effect
acut
respiratori
failur
need
improv
longerterm
followup
studi
multin
registri
must
develop
analys
effect
new
drug
updat
clinician
futur
trend
incid
acut
respiratori
failur
use
intens
care
patient
acut
respiratori
failur
target
improv
surviv
earli
icu
admiss
earli
identif
treatment
caus
acut
respiratori
failur
requir
evalu
larg
random
ise
control
trial
patient
substanti
life
expect
agre
undergo
icu
manag
ment
offer
unrestrict
access
diagnost
therapeut
strategi
greatest
challeng
identif
patient
high
risk
specif
diagnos
earlier
treatment
acut
respiratori
failur
caus
select
least
invas
diagnost
test
noninvas
approach
promis
still
need
refin
updat
combin
clinic
algorithm
sophist
test
genom
metagenom
proteom
transcriptom
noninvas
sampl
document
rule
infect
major
advanc
result
includ
surviv
benefit
shorter
icu
hospit
stay
length
reduc
cost
improv
patientreport
outcom
given
initi
oxygen
niv
strategi
unlik
associ
surviv
assess
patient
search
medlin
pubm
review
origin
articl
pulmonari
involv
immunocompromis
adult
publish
english
jan
april
use
term
respir
disord
mesh
immunocompromis
host
mesh
pneumonia
mesh
immunocompromis
host
mesh
respiratori
insuffici
mesh
immunocompromis
host
mesh
also
search
use
individu
term
leukaemia
lymphoma
solid
tumour
cancer
haematolog
malign
transplant
immunosuppress
drug
system
vascul
connect
tissu
diseas
primari
immunodefici
although
studi
retriev
publish
within
specifi
period
exclud
earlier
report
furthermor
search
refer
list
articl
identifi
search
strategi
person
file
use
origin
report
avail
patient
hiv
infect
scope
review
